What does SURPASS-3 actually establish about a GLP-1 receptor agonist?

Asked 15 May 2024Modified 2.2 years agoViewed 48k times

Stated plainly: SURPASS-3 · a GLP-1 receptor agonist.

I would like help reading this properly rather than being told what conclusion to reach.

I have the full report including the method section, so I can quote specifics if that helps.

How should I read this, and where are the traps?

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questionssemaglutide

semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questionscardiovascular

cardiovascular

Cardiovascular outcomes: the SELECT major-adverse-event result, SOUL, SUSTAIN 6 and REWIND, how to convert a hazard ratio into an absolute risk…

68 questions

shareeditfollowflag

askedrune_thoresen16k2815 May 2024

No answers yet

This question has not been answered. It has been viewed 48k times, which suggests the question is of interest and the answer is not obvious. If you can answer it with a source or a worked calculation, it will be read. See how to ask and answer.

Janoshik Analytical - Independent Third-Party Testing

HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.

Submit a sample

GL Biochem (Shanghai) Ltd. - Direct Synthesis

Founded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.

Visit GL Biochem

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.

Linked questions

11 How do I convert the SURPASS-2 hazard ratio into an absolute risk reduction?27 How do I convert the SURMOUNT-OSA hazard ratio into an absolute risk reduction?16 How do I convert the STEP 4 hazard ratio into an absolute risk reduction?1 What does SUSTAIN-6 actually establish about a GLP-1 receptor agonist?

Janoshik Analytical

Independent HPLC, identity and content testing. Chromatograms included with every report.

Submit a sample

GL Biochem (Shanghai)

Custom peptides and amino acids direct from the manufacturer since 1998. ISO 9001 / cGMP, batch documentation included.

Visit GL Biochem

Hot on the stack

What did the placebo arm of ATTAIN-1 report for dizziness?27 votes · 5 answers · 45k views Is resistance training seven times a week enough at 900 kcal a day?25 votes · 5 answers · 45k views Does early satiety at week eight of semaglutide usually resolve without a dose change?40 votes · 5 answers · 46k views What did the placebo arm of SURMOUNT-4 report for early satiety?37 votes · 5 answers · 47k views Would you re-test retatrutide after two weeks at room temperature, or accept the original certificate?27 votes · 5 answers · 47k views Does racemisation of dulaglutide at 40 °C show up as a loss of content or of purity?41 votes · 0 answers · 48k views Does constipation at week six of survodutide usually resolve without a dose change?36 votes · 4 answers · 49k views

The stack

Questions5.2k

Answers20k

Accepted3.1k

Unanswered739

Tags107

Users220

Vendors tracked20